A Possible Cluster of AEFI (Adverse Event Following Vaccination) Following AZD1222 (Covishield) Vaccination in India?
In order to mitigate the spread of the COVID-19 infection in India, the Indian government granted approval for the emergency use of Oxford-AstraZeneca’s COVID-19 (coronavirus disease 2019) vaccine AZD1222 (Covishield). The biggest large-scale COVID-19 vaccination drive in the world is being carried out continuously till date in India. In this research article, a possible cluster of AEFI (Adverse Event Following Vaccination) following AZD1222 (Covishield) vaccination in India has been briefly presented.
Read more about this article: https://juniperpublishers.com/ijoprs/IJOPRS.MS.ID.555676.php
Comments
Post a Comment